C ardiolaminopathies are autosomal dominant genetic diseases caused by mutations in the LMNA gene which encodes the nucleus envelope protein Lamin AC. 1 There are now 12 phenotypes associated with LMNA mutations, both autosomal dominant and recessive, the majority of which have cardiac involvement (http://omim.org/entry/150330). These include dilated cardiomyopathy (DCM) associated with conduction disease, atrial and ventricular arrhythmias, and phenotypes mimicking arrhythmogenic right ventricular cardiomyopathy. 2 
See Article by Hoorntje et al
Cardiolaminopathies are characterized by high arrhythmogenic risk 3 that may manifest in mildly dilated hearts and may be the first clinical presentation of the disease. Fatal arrhythmias may occur even when left ventricular dysfunction does not reach the cutoff value established by guidelines for implantable cardioverter-defibrillator implantation for the primary prevention of sudden death. 4 Clinical cardiologists involved in programs dedicated to familial cardiomyopathies are well aware of the arrhythmogenic risk of cardiolaminopathies. The latest ESC Guidelines for primary prevention of sudden cardiac death recommend (Class IIa; Level of Evidence B) implantable cardioverter-defibrillator in patients with DCM, a confirmed disease-causing LMNA mutation, and the following clinical risk factors: nonsustained ventricular tachycardia during ambulatory electrocardiographic monitoring, left ventricular ejection fraction <45% on initial evaluation, male sex, and nonmissense mutations. 
Impact of Genetic Diagnosis in Patients
The genetic diagnosis of laminopathy in DCM patients impacts therapeutic and prognostic strategies. For example, the percutaneous catheter ablation of sustained monomorphic ventricular tachycardia in LMNA cardiomyopathy could be an important consideration. Poor outcomes, including high rates of recurrence of arrhythmia, progression to end-stage heart failure, and high mortality, have been reported in patients with cardiolaminopathies, wherein 91% of patients experienced ≥1 ventricular tachycardia recurrence, 44% received or were awaiting mechanical circulatory support or transplant for endstage heart failure, and 26% died during a median 7-month follow-up. 6 Use of β-blockers in conduction disease should be postponed until after pacemaker implantation. Pregnancies in affected women should be discouraged, 1 and women diagnosed with LMNA mutations after pregnancy initiation should be closely monitored in specialized centers under high-risk maternal-fetal medicine care. Peripartum cardiomyopathy can be the first manifestation of disease 2 and, if not specifically investigated, may remain etiologically unlabeled, exposing the mother to adverse events. 7 Individually tailored clinical monitoring is warranted for all individuals with cardiolaminopathies. Cardiac magnetic resonance-detected myocardial fibrosis is common (88%), and segmental wall motion abnormalities correlate with the degree of enhancement 8 ; when detected in early phases of disease, myocardial fibrosis may represent a marker of subclinical cardiac disease. 9 
Impact of Genetic Diagnosis in Families
Clinical and genetic family screening provides early diagnoses in family members who are affected but asymptomatic or demonstrate imaging phenotype of early disease such as mild left ventricular remodeling or dysfunction without remodeling. The latter condition can now be classified as hypokinetic non-DCM. 10 Family screening also allows for the interpretation of pathogenicity of novel mutations, in particular missense mutations, and long-term monitoring contributes to segregation studies in families ( Figure) . The long-term surveillance of phenotypically healthy family members harboring an LMNA mutation is the most appropriate tool for characterizing the natural history of the disease.
11 Specifically, genetically affected and phenotypically healthy family members should be followed annually and receive neurohumoral antagonists when phenotypic changes become apparent. Unaffected women of childbearing age and relatives of affected patients should receive genetic counseling and testing, including information about their own risk and the risk of passing on the mutation to offspring. 1 Because the genetic diagnosis of laminopathy impacts medical decision-making in probands and families, LMNA should be tested in all DCM patients, especially those with associated conduction disease and arrhythmias. Founder LMNA Mutation
Variable Phenotypes With Different LMNA Mutations
The impact of LMNA mutations should be stratified by mutation type and effects on the structure and function of cardiac myocytes. In this issue, Hoorntje et al 12 present a unique series of 23 probands and 35 family members carrying the Dutch founder LMNA c.992G>A, p.(Arg331Gln) mutation that is associated with a phenotype reminiscent of other LMNA mutations, but with a more benign course. Compared with other pathogenic LMNA mutations, carriers of p.(Arg331Gln) demonstrate a better outcome for the composite end point of malignant ventricular arrhythmias, end-stage heart failure, or death. The pathogenetic effect of the mutation was demonstrated by in vitro functional studies in which the force development in membrane-permeabilized cardiomyocytes was reduced because of decreased myofibril density and by ultrastructural and immunofluorescence studies that demonstrated abnormalities of the nuclear envelope. The genetic, functional, and pathological studies in this case confirm the p.(Arg331Gln) LMNA mutation as the cause of cardiac manifestations similar to typical phenotypes of DCMs but with variable clinical severity. Beyond truncation predicting mutations, which constitute ≈20% of all LMNA mutations and are associated with clinical malignancy, missense mutations demonstrate variable penetrance and severity. Many missense mutations have been increasingly reported in different populations, and their pathogenicity is confirmed, for example, the malignant p.(Arg190Trp) and p.(Glu161Lys) mutations. 2, 3 Although these mutations do not predict a truncation effect on the protein, they are associated with decreased expression of the protein in affected myocardium, they segregate by age in families, and they cause similar clinical phenotypes. 13 Synonymous mutations can be equally damaging [eg, p.(Lys171Lys)] when affecting the splicing process with a truncation predicting effect on the protein.
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Effects of Mutations in the NextGeneration Sequencing Era
Next-generation sequencing (NGS) can analyze many disease genes per patient at a time, up to the clinical exome or whole genome sequencing. The common tests use multigene panels, including genes pertinent to the investigated phenotypes. These analyses provide pathogenic mutations, variants of uncertain significance, or incidental findings. The detection rate of genetic variants and mutations is faster than any functional study unraveling the functional role of each identified variant. Beyond in silico analysis that predicts, but does not demonstrate, the effects of the mutation/variant in the protein, immunohistochemical and electron microscopic studies of endomyocardial biopsy tissue may also uncover the effects of the mutations. 13 Experimental studies, including in vitro studies of cellular models as reported by Hoorntje et al 12 or experimental animal models, 15 can help identify potential functional effects of each given variant. However, these studies may be time-consuming, expensive, and complex, and usually test 1 variant/mutation rather than the complex genetic makeup of each single patient. When using multigene panel analysis, the detection of >1 variant/mutation per patient is common. The in vitro study of patient-specific inducible pluripotent stem cell-derived cardiac myocytes is a promising tool that could potentially integrate functional information 16 with both causative mutations and variants that can modify the phenotype but do not by themselves cause the disease. The different variants can have a biparental origin, and patient-specific inducible pluripotent stem cell-derived cardiac myocytes from different family members could shed light on the role of each genetic variant in patients with complex genetics.
A major contribution to the interpretation of the role of each mutation/variant is clinical screening of family members, followed by cascade genetic testing. In their series, Hoorntje et al 12 describe the case of a patient (F-II-1, Family F) who was a carrier of the LMNA p.(Arg331Gln) mutation and SCN5A mutation p.(Gly1319Val). The former was likely inherited from the father, who had no DCM, experienced gastric cancer and died of ischemic heart disease. The latter was inherited from the mother, who demonstrated a late-onset (67 years) arrhythmogenic phenotype (±18 000 PVCs per 24 hours) with mild left ventricular involvement (cardiac magnetic resonance; left ventricular ejection fraction 46%). 12 Given that the SCN5A mutation is reported as likely pathogenic (https://www.ncbi.nlm. nih.gov/clinvar/variation/67838/), but its effect when present as isolated defect seems to be clinically mild, the combination of the LMNA and SCN5A mutations likely contributes to the phenotype observed in the proband of the family (F-II-1). This example demonstrates how the genotype segregation study in families is critical to understanding the genotype-phenotype correlations in families. 12 In addition, mutations that do not segregate at baseline family screening may demonstrate agerelated penetrance, and the segregation may become manifest during long-term follow-up ( Figure) . The age-dependent manifestation of clinical traits in cardiolaminopathies underscores the importance of regular surveillance.
Founder Mutations in the LMNA Gene
Founder mutations are passed down over generations, wherein the given mutations are included in a DNA region that is identical to that of the founder (or identical by descent). 18 Hoorntje et al 12 report p.(Arg331Gln) as a founder mutation in autosomal dominant cardiolaminopathies with late-onset and mild cardiac phenotypes. In fact, mutation carriers shared a 1 Mb haplotype around the LMNA gene, with a combined LOD score of 3.46, suggesting a common founder. 12 The p.(Arg331Gln) mutation has been previously reported in 3 patients. One case was in Italy and was associated with late-onset DCM associated with conduction disease phenotype. 19 The second case was reported in Denmark, and the first manifestation of disease was cardiac arrest. 20 The third case was reported in the United States and was associated with skeletal muscle laminopathy (www.umd. be/LMNA/ mutation database, UMD-id 2158). There is no information about a possible origin from the Dutch population.
The LMNA p.(Arg331Gln) mutation now adds to other founder mutations [eg, PLN p.(Arg14del)] in genes causing cardiomyopathies in the Dutch population. 21 The haplotype characterization in future non-Dutch patients who are carriers of this mutation could help to clarify its origin. Founder mutations allow for extensive characterization of the associated phenotypes in large family clusters in which preclinical and presymptomatic diagnoses are feasible.
Conclusions
The identification and clinical characterization of LMNA mutations associated with mild and late-onset clinical phenotypes expand the spectrum of clinical severity of cardiolaminopathies, from malignant mutations with high arrhythmogenic risk to mutations with milder effects but with a phenotype similar to that typically occurring in cardiolaminopathy. In patients with cardiolaminopathy, multigene panel analysis may lead to the identification of other non-LMNA genetic variants potentially relevant for the clinical phenotype. These variants may modify the LMNA-related phenotype and induce apparent clinical discrepancies that are just the expression of a complex genetic background in families. Therefore, the responsibility of cardiologists in clinically monitoring families and not excluding a priori noncarrier members of the main/major mutation causing the clinical phenotype is critical. The answer lies in clinical family screening, with systematic monitoring and long-term follow-up of family members.
